newsfilter

Noubar Afeyan

Showing 1–3 of 3 interviews.

  1. Bloomberg Television49 min

    Trump, Xi, Putin To Meet as Jensen Huang Reportedly Eyes Nvidia Comeback

    Trump, Putin, Jensen Huang, Scott Bessent, Xi Jinping, Jean Boivin, Nadia Martin Wiggen, Bronwen Maddox, Noubar Afeyan, Francine Lacqua, Parmi Olson, Danny Lee, Min Min Lo

    Nvidia faces a potential leadership crisis as investors and staff urge CEO Jensen Huang's return amid FBI investigations, coinciding with Anthropic's impending IPO and critical earnings data that will test the sustainability of massive AI capital expenditure. This volatility unfolds against a diverging global economic backdrop where US resilience driven by AI wealth effects contrasts with revised European growth forecasts and Federal Reserve policies that may soon ease hawkish expectations. Meanwhile, geopolitical tensions over chip exports and regional security, coupled with new AI-biotech initiatives in the UK, are reshaping regulatory frameworks and supply chain strategies worldwide.

  2. Milken Institute1h 6m

    Engineering the Next Era of Human Health | Future of Health Summit 2026

    Meg Tirrell, Noubar Afeyan, Chris Boerner, David Rhew, Robert Stone

    The 2026 Future of Health Summit convened 200 leaders to confront the disparity between rapid medical advancements, such as cell therapy and AI-driven diagnostics, and persistent access barriers affecting millions of patients. Key executives from Flagship Pioneering, Bristol-Myers Squibb, and Microsoft detailed strategies to reduce clinical trial timelines by 30% while exposing systemic inefficiencies that drive a projected 9.2% rise in healthcare costs. In a major policy shift, the Milken Institute Women's Health Network launched the "Elevate Investment Initiative" to mobilize $1 billion in capital aimed at closing gender-specific health funding gaps and ensuring scalable implementation of precision medicine.

  3. Milken Institute1h 1m

    Where Is the Next Cure? | Global Conference 2024

    Alice Park, Noubar Afeyan, Aloe Blacc, Daphne Koller, Samarth Kulkarni, Pablo Legorreta

    Leading biotech executives and researchers are redefining the industry by shifting from chronic small-molecule management to precise, curative systems-based therapies like CRISPR and mRNA platforms. This transition, fueled by artificial intelligence and a "reverse translation" innovation model, has accelerated clinical timelines while projecting a $100 billion market for GLP-1 drugs and new organ-editing solutions. Despite regulatory hurdles and high initial costs for treatments like sickle cell gene editing, stakeholders anticipate that maturing technologies and scalable manufacturing will eventually democratize access to these transformative medical breakthroughs.